Paul Ferguson, MD
Neurology · Huntington, WVNPI 1447459946
Payments from drug & device makers
Across 1,317 payments — averaging $572.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$203K
- Biogen$134K
- Novartis$90K
- EMD Serono, Inc.$64K
- Amgen$43K
- TG Therapeutics, Inc.$43K
- plus $176K from 28 others
Across 1 payment — averaging $1079.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1K
What the payments were for
- Consulting fees$58,5379%
- Speaking & faculty fees$546,51084%
- Travel & lodging$20,9963%
- Food & beverage$22,1213%
- Education$6570%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 170 | $202,848 |
| Biogen | 161 | $134,002 |
| Novartis | 71 | $89,968 |
| EMD Serono, Inc. | 52 | $63,823 |
| Amgen(2 entities) | 37 | $43,484 |
| TG Therapeutics, Inc. | 31 | $43,254 |
| AbbVie(2 entities) | 458 | $42,646 |
| Sanofi | 17 | $38,272 |
| Genentech USA, Inc. | 34 | $37,567 |
| Johnson & Johnson | 32 | $37,406 |
| Janssen Research & Development, LLC | 2 | $14,069 |
| Bristol Myers Squibb | 4 | $1,556 |
| Eli Lilly | 2 | $1,195 |
| Neurocrine Biosciences, Inc. | 59 | $626 |
| Supernus Pharmaceuticals, Inc. | 67 | $607 |
| Argenx US, Inc. | 53 | $406 |
| Teva Pharmaceuticals USA, Inc. | 5 | $348 |
| Medtronic(2 entities) | 11 | $306 |
| Acadia Pharmaceuticals Inc | 6 | $248 |
| Abbott | 4 | $141 |
| Pfizer | 9 | $141 |
| Jazz Pharmaceuticals Inc. | 7 | $135 |
| Kyowa Kirin, Inc. | 2 | $135 |
| Lilly USA, LLC | 8 | $125 |
| Sanofi-aventis U.S. LLC | 1 | $99 |
| Amneal Pharmaceuticals LLC | 4 | $76 |
| SK Life Science, Inc. | 2 | $47 |
| Biohaven Pharmaceuticals, Inc. | 2 | $28 |
| MDD US Operations, LLC | 1 | $22 |
| Neurelis, Inc. | 1 | $22 |
| Sunovion Pharmaceuticals Inc. | 1 | $20 |
| Merz Pharmaceuticals, LLC | 1 | $20 |
| Lundbeck LLC | 1 | $15 |
| Adamas Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$753,670 in reported general payments places this provider in the 95th percentile of 93 neurology providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 115 | $1,003,134 |
| MavencladCladribine | 12 | $916,657 |
| TecfideraDimethyl Fumarate | 51 | $493,960 |
| FingolimodFingolimod Hcl | 142 | $263,484 |
| VumerityDiroximel Fumarate | 28 | $248,073 |
| CopaxoneGlatiramer Acetate | 33 | $206,627 |
| Vyvgart HytruloEfgartigimod-Hyaluronidas-Qvfc | 11 | $174,905 |
| RebifInterferon Beta-1a/Albumin | 12 | $124,121 |
| ZeposiaOzanimod Hydrochloride | 15 | $119,416 |
| AubagioTeriflunomide | 12 | $99,185 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 11 | $87,120 |
| UbrelvyUbrogepant | 51 | $61,190 |
| RytaryCarbidopa/Levodopa | 45 | $59,576 |
| Dimethyl Fumarate | 17 | $58,839 |
| Nurtec OdtRimegepant Sulfate | 55 | $54,845 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| EMD Serono, Inc.Mavenclad, Rebif | $63,823 | $1,040,77824 claims |
| BiogenTecfidera, Vumerity | $134,002 | $742,03379 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $348 | $206,62733 claims |
| Argenx US, Inc.Vyvgart Hytrulo | $406 | $174,90511 claims |
| SanofiAubagio | $38,272 | $99,18512 claims |
| AbbVieUbrelvy, Qulipta, Linzess | $42,646 | $85,96581 claims |
| Amneal Pharmaceuticals LLCRytary | $76 | $59,57645 claims |
| PfizerNurtec Odt | $141 | $54,84555 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 93 neurology providers in West Virginia.
Other neurology in Huntington
- Ronald BareboHuntington$28K
- Lindsay LittlehalesHuntington$17K
- Samrina HanifHuntington$12K
- Suresh KumarHuntington$12K
- Justin NolteHuntington$9K
- Kathryn ThorntonHuntington$3K
- Matthew BurtonHuntington$3K
- Christopher BurrellHuntington$1K
- Dharampreet SinghHuntington$971
- Gabrielle ConwayHuntington$914
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.